Significant Suppression of Multiple Sclerosis in the Mouse EAE Model Using the PrC-210 Aminothiol
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262110597 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von William E Fahl und 4 weiteren Autor:innen. Beteiligte Einrichtung: Obvia Pharmaceuticals Ltd., Mountain View, CA 94043, USA. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Multiple Sclerosis, Sulfhydryl Compounds. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Congressionally Directed Medical Research Programs, Obvia Pharmaceuticals, Ltd., Congressionally Directed Medical Research Program.
Abstract (Originalsprache)
Multiple sclerosis (MS) is a complex disease marked by chronic neuroinflammation and reactive oxygen species (ROS) toxicity in the central nervous system (CNS). Based on this ROS-driven mechanism, we tested whether PrC-210—a new aminothiol ROS scavenger—could lessen MS symptoms in mice with experimental autoimmune encephalomyelitis (EAE)-induced MS. Our goals were to assess the role of ROS in MS and evaluate the potential benefits of PrC-210 for managing MS. Mice with EAE received varying doses of PrC-210 under preventive and therapeutic protocols. Disease progression was measured using clinical scores and spinal cord histology. Safety was assessed by comparing the gastrointestinal and hematological toxicity between PrC-210 and dimethyl fumarate (DMF, Tecfidera’s active agent). PrC-210 reduced MS severity by up to 62% in paralysis scores versus those in the controls (p = 0.0001), whether used preventively or at the onset of paralysis. The group with the greatest decrease also showed the best spinal cord preservation and least demyelination. DMF caused toxicity at a dose that was ineffective, while PrC-210 showed no toxicity at effective levels. These findings suggest that the systemic administration of PrC-210 may offer a safe, effective MS treatment when started at symptom onset.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Obvia Pharmaceuticals Ltd., Mountain View, CA 94043, USA.
- Wisconsin Institutes for Medical Research, Department of Oncology, University of Wisconsin-Madison, Madison, WI 53705, USA.
ORCID-Profile: Sarah R Goesch, Hannah R Goesch
Förderung
- Congressionally Directed Medical Research Programs
- Obvia Pharmaceuticals, Ltd.
- Congressionally Directed Medical Research Program
Zitieren
APA
Fahl, W. E., Fahl, B. L., Goesch, S. R., Goesch, H. R., & Goesch, T. R. (2025). Significant Suppression of Multiple Sclerosis in the Mouse EAE Model Using the PrC-210 Aminothiol. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110597
Vancouver
Fahl WE, Fahl BL, Goesch SR, Goesch HR, Goesch TR. Significant Suppression of Multiple Sclerosis in the Mouse EAE Model Using the PrC-210 Aminothiol. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110597
BibTeX
@article{Fahl2025,
author = {Fahl, William E and Fahl, Bryan L and Goesch, Sarah R and Goesch, Hannah R and Goesch, Torsten R},
title = {Significant Suppression of Multiple Sclerosis in the Mouse EAE Model Using the PrC-210 Aminothiol},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262110597}
}
EUVIMED